COMPASS Pathways Overview
- Founded
- 2016
- Status
- Public
- Employees
- 116
- Stock Symbol
- CMPS
- Investments
- 2
COMPASS Pathways General Information
Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Contact Information
Website
www.compasspathways.com
Formerly Known As
COMPASS Pathways Technologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Pharmaceuticals
Stock Exchange
MEX
Primary Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
COMPASS Pathways Timeline
COMPASS Pathways Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore COMPASS Pathways‘s full profile, request access.
Request a free trialCOMPASS Pathways Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore COMPASS Pathways‘s full profile, request access.
Request a free trialCOMPASS Pathways Patents
COMPASS Pathways Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3138008-A1 | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | Pending | 17-Apr-2019 | 0000000000 | |
| CA-3138100-A1 | Treatment of depression and other various disorders with psilocybin | Pending | 17-Apr-2019 | 0000000000 | |
| CA-3138094-A1 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | Pending | 17-Apr-2019 | 0000000000 | |
| AU-2020259406-A1 | Treatment of depression and other various disorders with psilocybin | Pending | 17-Apr-2019 | 0000000000 | |
| AU-2018349279-A1 | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | Pending | 09-Oct-2017 | C07B63/00 |
COMPASS Pathways Executive Team (14)
COMPASS Pathways Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Annalisa Jenkins | COMPASS Pathways | Board Member | 000 0000 |
| David Norton | COMPASS Pathways | Board Member | 000 0000 |
| Ekaterina Malievskaia MD | COMPASS Pathways | Founder & Board Member | 000 0000 |
| Florian Brand | Self | Board Member | 000 0000 |
| George Goldsmith | COMPASS Pathways | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
COMPASS Pathways Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCOMPASS Pathways Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 14-Sep-2021 | 000000000 | Buildings and Property | 0000 0000 | |
| Delix Therapeutics | 06-Mar-2020 | Corporate | 00000 | Drug Discovery |